Literature DB >> 12050392

Long-term circulation of vaccine-derived poliovirus that causes paralytic disease.

Elena A Cherkasova1, Ekaterina A Korotkova, Maria L Yakovenko, Olga E Ivanova, Tatyana P Eremeeva, Konstantin M Chumakov, Vadim I Agol.   

Abstract

Successful implementation of the global poliomyelitis eradication program raises the problem of vaccination against poliomyelitis in the posteradication era. One of the options under consideration envisions completely stopping worldwide the use of the Sabin vaccine. This strategy is based on the assumption that the natural circulation of attenuated strains and their derivatives is strictly limited. Here, we report the characterization of a highly evolved derivative of the Sabin vaccine strain isolated in a case of paralytic poliomyelitis from a 7-month-old immunocompetent baby in an apparently adequately immunized population. Analysis of the genome of this isolate showed that it is a double (type 1-type 2-type 1) vaccine-derived recombinant. The number of mutations accumulated in both the type 1-derived and type 2-derived portions of the recombinant genome suggests that both had diverged from their vaccine predecessors approximately 2 years before the onset of the illness. This fact, along with other recent observations, points to the possibility of long-term circulation of Sabin vaccine strain derivatives associated with an increase in their neurovirulence. Comparison of genomic sequences of this and other evolved vaccine-derived isolates reveals some general features of natural poliovirus evolution. They include a very high preponderance and nonrandom distribution of synonymous substitutions, conservation of secondary structures of important cis-acting elements of the genome, and an apparently adaptive character of most of the amino acid mutations, with only a few of them occurring in the antigenic determinants. Another interesting feature is a frequent occurrence of tripartite intertypic recombinants with either type 1 or type 3 homotypic genomic ends.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050392      PMCID: PMC136293          DOI: 10.1128/jvi.76.13.6791-6799.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; J Balanant; A Macadam; D Otelea; M Combiescu; A A Combiescu; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee.

Authors:  P D Minor; A John; M Ferguson; J P Icenogle
Journal:  J Gen Virol       Date:  1986-04       Impact factor: 3.891

3.  Ending polio immunization.

Authors:  T F Kimman; M P Koopmans; H G van der Avoort
Journal:  Science       Date:  1998-02-06       Impact factor: 47.728

4.  SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling.

Authors:  N Guex; M C Peitsch
Journal:  Electrophoresis       Date:  1997-12       Impact factor: 3.535

5.  Studies on the recombination between RNA genomes of poliovirus: the primary structure and nonrandom distribution of crossover regions in the genomes of intertypic poliovirus recombinants.

Authors:  E A Tolskaya; L I Romanova; V M Blinov; E G Viktorova; A N Sinyakov; M S Kolesnikova; V I Agol
Journal:  Virology       Date:  1987-11       Impact factor: 3.616

6.  Three-dimensional structure of poliovirus at 2.9 A resolution.

Authors:  J M Hogle; M Chow; D J Filman
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

7.  Genetic analysis of the attenuation phenotype of poliovirus type 1.

Authors:  T Omata; M Kohara; S Kuge; T Komatsu; S Abe; B L Semler; A Kameda; H Itoh; M Arita; E Wimmer
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

8.  The genomes of attenuated and virulent poliovirus strains differ in their in vitro translation efficiencies.

Authors:  Y V Svitkin; S V Maslova; V I Agol
Journal:  Virology       Date:  1985-12       Impact factor: 3.616

9.  Three-dimensional structure of poliovirus serotype 1 neutralizing determinants.

Authors:  G S Page; A G Mosser; J M Hogle; D J Filman; R R Rueckert; M Chow
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

10.  Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient.

Authors:  O M Kew; R W Sutter; B K Nottay; M J McDonough; D R Prevots; L Quick; M A Pallansch
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

View more
  35 in total

1.  RNA recombination plays a major role in genomic change during circulation of coxsackie B viruses.

Authors:  M Steven Oberste; Silvia Peñaranda; Mark A Pallansch
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future.

Authors:  Ekaterina A Korotkova; Renee Park; Elena A Cherkasova; Galina Y Lipskaya; Konstantin M Chumakov; Esfir V Feldman; Olen M Kew; Vadim I Agol
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

3.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

4.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

6.  A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region.

Authors:  Minetaro Arita; Shuang-Li Zhu; Hiromu Yoshida; Tetsuo Yoneyama; Tatsuo Miyamura; Hiroyuki Shimizu
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

7.  Use of a multiple restriction fragment length polymorphism method for detecting vaccine-derived polioviruses in clinical samples.

Authors:  Natalia I Romanenkova; Sophie Guillot; Nadejda R Rozaeva; Radu Crainic; Maina A Bichurina; Francis Delpeyroux
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

8.  Detection of unusual mutation within the VP1 region of different re-isolates of poliovirus Sabin vaccine.

Authors:  Evaggelos Dedepsidis; Ioannis Karakasiliotis; Eleni Paximadi; Zaharoula Kyriakopoulou; Dimitrios Komiotis; Panayotis Markoulatos
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

9.  Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine.

Authors:  E A Cherkasova; M L Yakovenko; G V Rezapkin; E A Korotkova; O E Ivanova; T P Eremeeva; L I Krasnoproshina; N I Romanenkova; N R Rozaeva; L Sirota; V I Agol; K M Chumakov
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 10.  New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.

Authors:  Konstantin Chumakov; Ellie Ehrenfeld
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.